{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,2]],"date-time":"2026-07-02T00:46:46Z","timestamp":1782953206999,"version":"3.54.5"},"reference-count":53,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,4,27]],"date-time":"2026-04-27T00:00:00Z","timestamp":1777248000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2026,7,2]],"date-time":"2026-07-02T00:00:00Z","timestamp":1782950400000},"content-version":"vor","delay-in-days":66,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"funder":[{"name":"Benefactors, Department of Development, Center for Regenerative Biotherapeutics in Mayo Clinic"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["npj Vaccines"],"DOI":"10.1038\/s41541-026-01466-0","type":"journal-article","created":{"date-parts":[[2026,4,27]],"date-time":"2026-04-27T03:16:44Z","timestamp":1777259804000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Preclinical efficacy of dendritic cells loaded with newly identified HPV11 E6-derived CD8+ T cell epitopes"],"prefix":"10.1038","volume":"11","author":[{"given":"Laurie","family":"Baert","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chao","family":"Gu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Agnes","family":"Yang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"HyeMee","family":"Joo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Richard","family":"Kennedy","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kieth","family":"Knutson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David G.","family":"Lott","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"SangKon","family":"Oh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,4,27]]},"reference":[{"key":"1466_CR1","doi-asserted-by":"publisher","first-page":"278","DOI":"10.1002\/ijc.20244","volume":"111","author":"N Munoz","year":"2004","unstructured":"Munoz, N. et al. Against which human papillomavirus types shall we vaccinate and screen? The international perspective. Int. J. Cancer 111, 278\u2013285 (2004).","journal-title":"Int. J. Cancer"},{"key":"1466_CR2","doi-asserted-by":"publisher","first-page":"F12","DOI":"10.1016\/j.vaccine.2012.07.055","volume":"30","author":"D Forman","year":"2012","unstructured":"Forman, D. et al. Global burden of human papillomavirus and related diseases. Vaccine 30, F12\u201323 (2012).","journal-title":"Vaccine"},{"key":"1466_CR3","doi-asserted-by":"publisher","first-page":"455","DOI":"10.1111\/j.1600-0463.2010.02617.x","volume":"118","author":"VR Bonagura","year":"2010","unstructured":"Bonagura, V. R. et al. Recurrent respiratory papillomatosis: a complex defect in immune responsiveness to human papillomavirus-6 and -11. APMIS 118, 455\u2013470 (2010).","journal-title":"APMIS"},{"key":"1466_CR4","doi-asserted-by":"publisher","first-page":"291","DOI":"10.1016\/j.amjoto.2009.02.019","volume":"31","author":"HW Lin","year":"2010","unstructured":"Lin, H. W. et al. Malignant transformation of a highly aggressive human papillomavirus type 11-associated recurrent respiratory papillomatosis. Am. J. Otolaryngol. 31, 291\u2013296 (2010).","journal-title":"Am. J. Otolaryngol."},{"key":"1466_CR5","doi-asserted-by":"publisher","first-page":"7","DOI":"10.1016\/j.ijporl.2009.09.004","volume":"74","author":"AJ Donne","year":"2010","unstructured":"Donne, A. J., Hampson, L., Homer, J. J. & Hampson, I. N. The role of HPV type in recurrent respiratory papillomatosis. Int. J. Pediatr. Otorhinolaryngol. 74, 7\u201314 (2010).","journal-title":"Int. J. Pediatr. Otorhinolaryngol."},{"key":"1466_CR6","doi-asserted-by":"publisher","first-page":"1906","DOI":"10.1097\/01.mlg.0000147918.81733.49","volume":"114","author":"PM Reidy","year":"2004","unstructured":"Reidy, P. M. et al. Integration of human papillomavirus type 11 in recurrent respiratory papilloma-associated cancer. Laryngoscope 114, 1906\u20131909 (2004).","journal-title":"Laryngoscope"},{"key":"1466_CR7","doi-asserted-by":"publisher","first-page":"vii243","DOI":"10.1093\/annonc\/mdq454","volume":"21","author":"S Syrjanen","year":"2010","unstructured":"Syrjanen, S. The role of human papillomavirus infection in head and neck cancers. Ann. Oncol. 21, vii243\u2013245 (2010).","journal-title":"Ann. Oncol."},{"key":"1466_CR8","doi-asserted-by":"publisher","first-page":"200294","DOI":"10.1016\/j.tvr.2024.200294","volume":"18","author":"M Rahmoun","year":"2024","unstructured":"Rahmoun, M. et al. Genomic diversity of HPV6 and HPV11 in recurrent respiratory papillomatosis: association with malignant transformation in the lungs and clinical outcomes. Tumour Virus Res. 18, 200294 (2024).","journal-title":"Tumour Virus Res."},{"key":"1466_CR9","doi-asserted-by":"publisher","first-page":"1161","DOI":"10.1002\/ijc.30821","volume":"141","author":"MT Faber","year":"2017","unstructured":"Faber, M. T. et al. Prevalence and type distribution of human papillomavirus in squamous cell carcinoma and intraepithelial neoplasia of the vulva. Int. J. Cancer 141, 1161\u20131169 (2017).","journal-title":"Int. J. Cancer"},{"key":"1466_CR10","doi-asserted-by":"publisher","first-page":"145","DOI":"10.1016\/S1470-2045(18)30682-X","volume":"20","author":"TB Olesen","year":"2019","unstructured":"Olesen, T. B. et al. Prevalence of human papillomavirus DNA and p16(INK4a) in penile cancer and penile intraepithelial neoplasia: a systematic review and meta-analysis. Lancet Oncol. 20, 145\u2013158 (2019).","journal-title":"Lancet Oncol."},{"key":"1466_CR11","doi-asserted-by":"publisher","first-page":"c3493","DOI":"10.1136\/bmj.c3493","volume":"341","author":"FIIS Group","year":"2010","unstructured":"Group, F. I. I. S. et al. Four year efficacy of prophylactic human papillomavirus quadrivalent vaccine against low grade cervical, vulvar, and vaginal intraepithelial neoplasia and anogenital warts: randomised controlled trial. BMJ 341, c3493 (2010).","journal-title":"BMJ"},{"key":"1466_CR12","doi-asserted-by":"publisher","unstructured":"Hampson, I. N. Effects of the prophylactic HPV vaccines on HPV type prevalence and cervical pathology. Viruses 14, https:\/\/doi.org\/10.3390\/v14040757 (2022).","DOI":"10.3390\/v14040757"},{"key":"1466_CR13","doi-asserted-by":"publisher","first-page":"2785","DOI":"10.1111\/jsm.12670","volume":"11","author":"ER Coskuner","year":"2014","unstructured":"Coskuner, E. R., Ozkan, T. A., Karakose, A., Dillioglugil, O. & Cevik, I. Impact of the quadrivalent HPV vaccine on disease recurrence in men exposed to HPV Infection: a randomized study. J. Sex Med. 11, 2785\u20132791 (2014).","journal-title":"J. Sex Med."},{"key":"1466_CR14","doi-asserted-by":"publisher","first-page":"401","DOI":"10.1056\/NEJM198808183190704","volume":"319","author":"GB Healy","year":"1988","unstructured":"Healy, G. B. et al. Treatment of recurrent respiratory papillomatosis with human leukocyte interferon. N Engl. J. Med. 319, 401\u2013407 (1988).","journal-title":"N Engl. J. Med."},{"key":"1466_CR15","doi-asserted-by":"publisher","first-page":"1163","DOI":"10.1001\/archotol.1988.01860220097032","volume":"114","author":"BG Leventhal","year":"1988","unstructured":"Leventhal, B. G. et al. Randomized surgical adjuvant trial of interferon alfa-n1 in recurrent papillomatosis. Arch. Otolaryngol. Head Neck Surg. 114, 1163\u20131169 (1988).","journal-title":"Arch. Otolaryngol. Head Neck Surg."},{"key":"1466_CR16","doi-asserted-by":"publisher","first-page":"119","DOI":"10.1186\/s40425-019-0603-3","volume":"7","author":"CT Allen","year":"2019","unstructured":"Allen, C. T. et al. Safety and clinical activity of PD-L1 blockade in patients with aggressive recurrent respiratory papillomatosis. J. Immunother. Cancer 7, 119 (2019).","journal-title":"J. Immunother. Cancer"},{"key":"1466_CR17","doi-asserted-by":"publisher","first-page":"E27","DOI":"10.1002\/lary.26847","volume":"128","author":"J Ahn","year":"2018","unstructured":"Ahn, J., Bishop, J. A., Roden, R. B. S., Allen, C. T. & Best, S. R. A. The PD-1 and PD-L1 pathway in recurrent respiratory papillomatosis. Laryngoscope 128, E27\u2013E32 (2018).","journal-title":"Laryngoscope"},{"key":"1466_CR18","doi-asserted-by":"publisher","first-page":"eadj0740","DOI":"10.1126\/scitranslmed.adj0740","volume":"15","author":"SM Norberg","year":"2023","unstructured":"Norberg, S. M. et al. The tumor microenvironment state associates with response to HPV therapeutic vaccination in patients with respiratory papillomatosis. Sci.Transl. Med. 15, eadj0740 (2023).","journal-title":"Sci.Transl. Med."},{"key":"1466_CR19","doi-asserted-by":"publisher","first-page":"5546","DOI":"10.1128\/JVI.02166-10","volume":"85","author":"NJ Genovese","year":"2011","unstructured":"Genovese, N. J., Broker, T. R. & Chow, L. T. Nonconserved lysine residues attenuate the biological function of the low-risk human papillomavirus E7 protein. J. Virol. 85, 5546\u20135554 (2011).","journal-title":"J. Virol."},{"key":"1466_CR20","doi-asserted-by":"publisher","first-page":"3087","DOI":"10.1002\/lary.30749","volume":"133","author":"T Mau","year":"2023","unstructured":"Mau, T. et al. Interim results of a phase 1\/2 open-label study of INO-3107 for HPV-6 and\/or HPV-11-associated recurrent respiratory papillomatosis. Laryngoscope 133, 3087\u20133093 (2023).","journal-title":"Laryngoscope"},{"key":"1466_CR21","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-025-56729-6","volume":"16","author":"MP Morrow","year":"2025","unstructured":"Morrow, M. P. et al. DNA immunotherapy for recurrent respiratory papillomatosis (RRP): phase 1\/2 study assessing efficacy, safety, and immunogenicity of INO-3107. Nat. Commun. 16, 1518 (2025).","journal-title":"Nat. Commun."},{"key":"1466_CR22","doi-asserted-by":"publisher","first-page":"504","DOI":"10.1002\/lary.20745","volume":"120","author":"S Peng","year":"2010","unstructured":"Peng, S. et al. Characterization of human papillomavirus type 11-specific immune responses in a preclinical model. Laryngoscope 120, 504\u2013510 (2010).","journal-title":"Laryngoscope"},{"key":"1466_CR23","doi-asserted-by":"publisher","first-page":"2713","DOI":"10.1002\/lary.26737","volume":"127","author":"J Ahn","year":"2017","unstructured":"Ahn, J. et al. Immunologic responses to a novel DNA vaccine targeting human papillomavirus-11 E6E7. Laryngoscope 127, 2713\u20132720 (2017).","journal-title":"Laryngoscope"},{"key":"1466_CR24","doi-asserted-by":"publisher","first-page":"470","DOI":"10.4161\/hv.19180","volume":"8","author":"TH Shin","year":"2012","unstructured":"Shin, T. H. et al. Induction of robust cellular immunity against HPV6 and HPV11 in mice by DNA vaccine encoding for E6\/E7 antigen. Hum. Vaccin Immunother. 8, 470\u2013478 (2012).","journal-title":"Hum. Vaccin Immunother."},{"key":"1466_CR25","doi-asserted-by":"publisher","first-page":"1956","DOI":"10.4161\/hv.25373","volume":"9","author":"S Anguille","year":"2013","unstructured":"Anguille, S. et al. Interleukin-15 dendritic cells as vaccine candidates for cancer immunotherapy. Hum. Vaccin Immunother. 9, 1956\u20131961 (2013).","journal-title":"Hum. Vaccin Immunother."},{"key":"1466_CR26","doi-asserted-by":"publisher","first-page":"658","DOI":"10.3389\/fimmu.2018.00658","volume":"9","author":"HH Van Acker","year":"2018","unstructured":"Van Acker, H. H. et al. Interleukin-15-cultured dendritic cells enhance anti-tumor gamma delta T cell functions through IL-15 secretion. Front. Immunol. 9, 658 (2018).","journal-title":"Front. Immunol."},{"key":"1466_CR27","doi-asserted-by":"publisher","first-page":"119","DOI":"10.1016\/j.trecan.2017.12.007","volume":"4","author":"M Saxena","year":"2018","unstructured":"Saxena, M. & Bhardwaj, N. Re-emergence of dendritic cell vaccines for cancer treatment. Trends Cancer 4, 119\u2013137 (2018).","journal-title":"Trends Cancer"},{"key":"1466_CR28","doi-asserted-by":"publisher","first-page":"330","DOI":"10.1200\/JCO.2010.30.7744","volume":"29","author":"H Okada","year":"2011","unstructured":"Okada, H. et al. Induction of CD8+ T-cell responses against novel glioma-associated antigen peptides and clinical activity by vaccinations with alpha-type 1 polarized dendritic cells and polyinosinic-polycytidylic acid stabilized by lysine and carboxymethylcellulose in patients with recurrent malignant glioma. J. Clin. Oncol. 29, 330\u2013336 (2011).","journal-title":"J. Clin. Oncol."},{"key":"1466_CR29","doi-asserted-by":"publisher","first-page":"1589","DOI":"10.1007\/s00262-008-0489-2","volume":"57","author":"AC Boullart","year":"2008","unstructured":"Boullart, A. C. et al. Maturation of monocyte-derived dendritic cells with Toll-like receptor 3 and 7\/8 ligands combined with prostaglandin E2 results in high interleukin-12 production and cell migration. Cancer Immunol. Immunother. 57, 1589\u20131597 (2008).","journal-title":"Cancer Immunol. Immunother."},{"key":"1466_CR30","doi-asserted-by":"publisher","first-page":"4914","DOI":"10.4049\/jimmunol.1302929","volume":"193","author":"NJ Maney","year":"2014","unstructured":"Maney, N. J., Reynolds, G., Krippner-Heidenreich, A. & Hilkens, C. M. U. Dendritic cell maturation and survival are differentially regulated by TNFR1 and TNFR2. J. Immunol. 193, 4914\u20134923 (2014).","journal-title":"J. Immunol."},{"key":"1466_CR31","doi-asserted-by":"publisher","first-page":"453","DOI":"10.1089\/152581600419116","volume":"9","author":"Z Zheng","year":"2000","unstructured":"Zheng, Z. et al. Generation of dendritic cells from adherent cells of cord blood by culture with granulocyte-macrophage colony-stimulating factor, interleukin-4, and tumor necrosis factor-alpha. J. Hematother. Stem Cell Res. 9, 453\u2013464 (2000).","journal-title":"J. Hematother. Stem Cell Res."},{"key":"1466_CR32","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-020-18962-z","volume":"11","author":"MS Block","year":"2020","unstructured":"Block, M. S. et al. Th17-inducing autologous dendritic cell vaccination promotes antigen-specific cellular and humoral immunity in ovarian cancer patients. Nat. Commun. 11, 5173 (2020).","journal-title":"Nat. Commun."},{"key":"1466_CR33","doi-asserted-by":"publisher","unstructured":"Luo, Y. et al. Th17-inducing dendritic cell vaccines stimulate effective CD4 T cell-dependent antitumor immunity in ovarian cancer that overcomes resistance to immune checkpoint blockade. J. Immunother. Cancer 11, https:\/\/doi.org\/10.1136\/jitc-2023-007661 (2023).","DOI":"10.1136\/jitc-2023-007661"},{"key":"1466_CR34","doi-asserted-by":"publisher","first-page":"1941","DOI":"10.3892\/ol.2016.4854","volume":"12","author":"X Xu","year":"2016","unstructured":"Xu, X. et al. Expression of Th1- Th2- and Th17-associated cytokines in laryngeal carcinoma. Oncol. Lett. 12, 1941\u20131948 (2016).","journal-title":"Oncol. Lett."},{"key":"1466_CR35","doi-asserted-by":"publisher","DOI":"10.1038\/s41541-021-00341-4","volume":"6","author":"C Zenobia","year":"2021","unstructured":"Zenobia, C., Herpoldt, K. L. & Freire, M. Is the oral microbiome a source to enhance mucosal immunity against infectious diseases? NPJ Vaccines 6, 80 (2021).","journal-title":"NPJ Vaccines"},{"key":"1466_CR36","doi-asserted-by":"publisher","first-page":"1030","DOI":"10.1128\/IAI.01389-13","volume":"82","author":"MC Ferreira","year":"2014","unstructured":"Ferreira, M. C. et al. Interleukin-17-induced protein lipocalin 2 is dispensable for immunity to oral candidiasis. Infect Immun. 82, 1030\u20131035 (2014).","journal-title":"Infect Immun."},{"key":"1466_CR37","doi-asserted-by":"publisher","first-page":"203","DOI":"10.1016\/j.chom.2018.01.007","volume":"23","author":"L Chung","year":"2018","unstructured":"Chung, L. et al. Bacteroides fragilis toxin coordinates a pro-carcinogenic inflammatory cascade via targeting of colonic epithelial cells. Cell Host Microbe 23, 203\u2013214.e205 (2018).","journal-title":"Cell Host Microbe"},{"key":"1466_CR38","doi-asserted-by":"publisher","first-page":"A8","DOI":"10.1016\/S0264-410X(02)00382-1","volume":"20","author":"AW Lee","year":"2002","unstructured":"Lee, A. W. et al. A clinical grade cocktail of cytokines and PGE2 results in uniform maturation of human monocyte-derived dendritic cells: implications for immunotherapy. Vaccine 20, A8\u2013A22 (2002).","journal-title":"Vaccine"},{"key":"1466_CR39","doi-asserted-by":"publisher","first-page":"8237","DOI":"10.4049\/jimmunol.181.12.8237","volume":"181","author":"J Rowley","year":"2008","unstructured":"Rowley, J., Monie, A., Hung, C. F. & Wu, T. C. Inhibition of tumor growth by NK1.1+ cells and CD8+ T cells activated by IL-15 through receptor beta\/common gamma signaling in trans. J. Immunol. 181, 8237\u20138247 (2008).","journal-title":"J. Immunol."},{"key":"1466_CR40","doi-asserted-by":"publisher","first-page":"6633","DOI":"10.4049\/jimmunol.1004181","volume":"186","author":"EA James","year":"2011","unstructured":"James, E. A. et al. Papillomavirus-specific CD4+ T cells exhibit reduced STAT-5 signaling and altered cytokine profiles in patients with recurrent respiratory papillomatosis. J. Immunol. 186, 6633\u20136640 (2011).","journal-title":"J. Immunol."},{"key":"1466_CR41","doi-asserted-by":"publisher","first-page":"e0127153","DOI":"10.1371\/journal.pone.0127153","volume":"10","author":"NP Mayor","year":"2015","unstructured":"Mayor, N. P. et al. HLA typing for the next generation. PLoS ONE 10, e0127153 (2015).","journal-title":"PLoS ONE"},{"key":"1466_CR42","doi-asserted-by":"publisher","first-page":"323","DOI":"10.1146\/annurev.immunol.16.1.323","volume":"16","author":"E Pamer","year":"1998","unstructured":"Pamer, E. & Cresswell, P. Mechanisms of MHC class I-restricted antigen processing. Annu. Rev. Immunol. 16, 323\u2013358 (1998).","journal-title":"Annu. Rev. Immunol."},{"key":"1466_CR43","doi-asserted-by":"publisher","first-page":"237","DOI":"10.1126\/science.7517574","volume":"265","author":"H de la Salle","year":"1994","unstructured":"de la Salle, H. et al. Homozygous human TAP peptide transporter mutation in HLA class I deficiency. Science 265, 237\u2013241 (1994).","journal-title":"Science"},{"key":"1466_CR44","doi-asserted-by":"publisher","first-page":"72","DOI":"10.1038\/icb.2009.61","volume":"88","author":"A Theodoratos","year":"2010","unstructured":"Theodoratos, A. et al. Mouse strains with point mutations in TAP1 and TAP2. Immunol. Cell Biol. 88, 72\u201378 (2010).","journal-title":"Immunol. Cell Biol."},{"key":"1466_CR45","doi-asserted-by":"publisher","first-page":"1883","DOI":"10.1084\/jem.182.6.1883","volume":"182","author":"PM van Endert","year":"1995","unstructured":"van Endert, P. M. et al. The peptide-binding motif for the human transporter associated with antigen processing. J. Exp. Med. 182, 1883\u20131895 (1995).","journal-title":"J. Exp. Med."},{"key":"1466_CR46","doi-asserted-by":"publisher","first-page":"1133","DOI":"10.1002\/eji.1830250444","volume":"25","author":"J Neefjes","year":"1995","unstructured":"Neefjes, J. et al. Analysis of the fine specificity of rat, mouse and human TAP peptide transporters. Eur. J. Immunol. 25, 1133\u20131136 (1995).","journal-title":"Eur. J. Immunol."},{"key":"1466_CR47","doi-asserted-by":"publisher","first-page":"e2402","DOI":"10.1371\/journal.pone.0002402","volume":"3","author":"A Burgevin","year":"2008","unstructured":"Burgevin, A. et al. A detailed analysis of the murine TAP transporter substrate specificity. PLoS ONE 3, e2402 (2008).","journal-title":"PLoS ONE"},{"key":"1466_CR48","doi-asserted-by":"publisher","first-page":"625","DOI":"10.1002\/(SICI)1521-4141(199802)28:02<625::AID-IMMU625>3.0.CO;2-I","volume":"28","author":"VM Braud","year":"1998","unstructured":"Braud, V. M., McMichael, A. J. & Cerundolo, V. Differential processing of influenza nucleoprotein in human and mouse cells. Eur. J. Immunol. 28, 625\u2013635 (1998).","journal-title":"Eur. J. Immunol."},{"key":"1466_CR49","doi-asserted-by":"publisher","first-page":"46461","DOI":"10.1074\/jbc.M308816200","volume":"278","author":"L Sesma","year":"2003","unstructured":"Sesma, L., Alvarez, I., Marcilla, M., Paradela, A. & Lopez de Castro, J. A. Species-specific differences in proteasomal processing and tapasin-mediated loading influence peptide presentation by HLA-B27 in murine cells. J. Biol. Chem. 278, 46461\u201346472 (2003).","journal-title":"J. Biol. Chem."},{"key":"1466_CR50","doi-asserted-by":"publisher","first-page":"471","DOI":"10.1111\/j.1600-0463.2010.02618.x","volume":"118","author":"D Pim","year":"2010","unstructured":"Pim, D. & Banks, L. Interaction of viral oncoproteins with cellular target molecules: infection with high-risk vs low-risk human papillomaviruses. APMIS 118, 471\u2013493 (2010).","journal-title":"APMIS"},{"key":"1466_CR51","doi-asserted-by":"publisher","first-page":"35","DOI":"10.1016\/j.coi.2017.06.003","volume":"47","author":"M Saxena","year":"2017","unstructured":"Saxena, M. & Bhardwaj, N. Turbocharging vaccines: emerging adjuvants for dendritic cell based therapeutic cancer vaccines. Curr. Opin. Immunol. 47, 35\u201343 (2017).","journal-title":"Curr. Opin. Immunol."},{"key":"1466_CR52","doi-asserted-by":"publisher","first-page":"763","DOI":"10.1007\/978-1-4939-3387-7_44","volume":"1403","author":"RL Sabado","year":"2016","unstructured":"Sabado, R. L., Meseck, M. & Bhardwaj, N. Dendritic cell vaccines. Methods Mol. Biol. 1403, 763\u2013777 (2016).","journal-title":"Methods Mol. Biol."},{"key":"1466_CR53","doi-asserted-by":"publisher","first-page":"57","DOI":"10.4049\/jimmunol.2300029","volume":"211","author":"C Gu","year":"2023","unstructured":"Gu, C. et al. Cancer cells promote immune regulatory function of macrophages by upregulating scavenger receptor MARCO expression. J. Immunol. 211, 57\u201370 (2023).","journal-title":"J. Immunol."}],"container-title":["npj Vaccines"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41541-026-01466-0","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41541-026-01466-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41541-026-01466-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,7,2]],"date-time":"2026-07-02T00:06:20Z","timestamp":1782950780000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41541-026-01466-0"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,4,27]]},"references-count":53,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["1466"],"URL":"https:\/\/doi.org\/10.1038\/s41541-026-01466-0","relation":{},"ISSN":["2059-0105"],"issn-type":[{"value":"2059-0105","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,4,27]]},"assertion":[{"value":"14 September 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"16 April 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"27 April 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare no competing interests.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"129"}}